Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662

British Journal of Clinical Pharmacology

Volumn 79, Issue 5, 2015, Pages 809-819

  Yu, Huixin ^a   Steeghs, Neeltje ^a   Kloth, Jacqueline S L ^b   De Wit, Djoeke ^c   Van Hasselt, J G Coen ^d   Van Erp, Nielka P ^e   Beijnen, Jos H ^a,f   Schellens, Jan H M ^a,f   Mathijssen, Ron H J ^b   Huitema, Alwin D R ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UTRECHT UNIVERSITY   (Netherlands)

Author keywords

modelling; pharmacokinetics; semi physiological model; SU12662; sunitinib; therapeutic drug monitoring

Indexed keywords

N DEETHYLSUNITINIB; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; BODY WEIGHT; CANCER PATIENT; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MINIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SIMULATION; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; DOSE RESPONSE; DRUG MONITORING; METABOLIC CLEARANCE RATE; METABOLISM; PROCEDURES;

ANTINEOPLASTIC AGENTS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; INDOLES; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PYRROLES;

EID: 84928319745     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12550     Document Type: Article

References (41)

1. SUTENT 12.5 mg hard capsules. Summary of product characteristics. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000687/WC500057737.pdf (last accessed 23 December 2013).
2. Bello C, Sherman L, Zhou J,. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006; 17: 353-358.
3. Sweeney CJ, Chiorean EG, Verschraegen CF, Lee FC, Jones S, Royce M, Tye L, Liau KF, Bello A, Chao R, Burris HA,. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol 2010; 28: 4513-4520.
4. Starling N, Vázquez-Mazõn F, Cunningham D, Chau I, Tabernero J, Ramos FJ, Iveson TJ, Saunders MP, Aranda E, Countouriotis AM, Ruiz-Garcia A, Wei G, Tursi JM, Guillen-Ponce C, Carrato A,. A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Ann Oncol 2012; 23: 119-127.
5. Britten C, Kabbinavar F, Hecht J,. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008; 61: 515-524.
6. Speed B, Bu H, Pool WF, Peng GW, Wu EY, Patyna S, Bello C, Kang P,. Pharmacokinetics, distribution, and metabolism of sunitinib in rats, monkeys, and humans. Drug Metab Dispos 2012; 40: 539-555.
7. Yu H, Steeghs N, Nijenhuis CM, Schellens JHM, Beijnen JH, Huitema ADR,. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet 2014; 53: 305-325.
8. Mathijssen RHJ, Sparreboom A, Verweij J,. Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol 2014; 11: 272-281.
9. Van Leeuwen RWF, van Gelder T, Mathijssen RHJ, Jansman FGA,. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 2014; 15: e315-326.
10. Lankheet NAG, Kloth JSL, Gadellaa-van Hooijdonk CGM, Cirkel GA, Mathijssen RHJ, Lolkema MPJK, Schellens JHM, Voest EE, Sleijfer S, de Jonge MJA, Haanen JBAG, Beijnen JH, Huitema ADR, Steeghs N,. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer 2014; 110: 2441-2449.
11. Gotta V, Widmer N, Montemurro M, Leyvraz S, Haouala A, Decosterd LA, Csajka C, Buclin T,. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels. Clin Pharmacokinet 2012; 51: 187-201.
12. Zhao W, Cella M, Della Pasqua O, Burger D, Jacqz-Aigrain E,. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers. Br J Clin Pharmacol 2012; 73: 641-650.
13. Gordi T, Xie R, Huong NV, Huong DX, Karlsson MO, Ashton M,. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br J Clin Pharmacol 2005; 59: 189-198.
14. Frechen S, Junge L, Saari TI, Suleiman AA, Rokitta D, Neuvonen PJ, Olkkola KT, Fuhr U,. A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole. Clin Pharmacokinet 2013; 52: 763-781.
15. Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, Jaehde U, Kirchheiner J, Fuhr U,. Assessment of activity levels for CYP2D6∗1, CYP2D6∗2, and CYP2D6∗41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther 2010; 88: 643-651.
16. Houk BE, Bello CL, Kang D, Amantea M,. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin cancer Res 2009; 15: 2497-2506.
17. Lindauer A, Di Gion P, Kanefendt F, Tomalik-Scharte D, Kinzig M, Rodamer M, Dodos F, Sörgel F, Fuhr U, Jaehde U,. Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin Pharmacol Ther 2010; 87: 601-608.
18. Kloth JSL, Klümpen H-J, Yu H, Eechoute K, Samer CF, Kam BLR, Huitema ADR, Daali Y, Zwinderman AH, Balakrishnar B, Bennink RJ, Wong M, Schellens JHM, Mathijssen RHJ, Gurney H,. Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. Clin Pharmacokinet 2014; 53: 261-269.
19. Diekstra MHM, Klümpen HJ, Lolkema MPJK, Yu H, Kloth JSL, Gelderblom H, van Schaik RHN, Gurney H, Swen JJ, Huitema ADR, Steeghs N, Mathijssen RHJ,. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin Pharmacol Ther 2014; 96: 81-89.
20. Kloth JS, Binkhorst L, de Bruijn P, Burger H, Hamberg P, Wiemer E,. Effect of dosing time on sunitinib pharmacokinetics. Eur J Cancer 2013; 49: 692.
21. De Wit D, Gelderblom H, Sparreboom A, den Hartigh J, den Hollander M, König-Quartel JMC, Hessing T, Guchelaar HJ, van Erp NP,. Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. Cancer Chemother Pharmacol 2014; 73: 87-96.
22. Beal SL, Sheiner LB,. NONMEM User Guides. Ellicott City, MD, USA: Icon Development Solutions, 1989.
23. Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR,. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 2011; 101: 72-79.
24. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2008.
25. Lindbom L, Pihlgren P, Jonsson EN, Jonsson N,. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79: 241-257.
26. Jonsson EN, Karlsson MO,. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
27. Soetaert K, Petzoldt T, Setzer R,. Solving Differential Equations in R: package deSolve. J Stat Softw 2010; 33: 1-25.
28. Carlisle KM, Halliwell M, Read AE, Wells PN,. Estimation of total hepatic blood flow by duplex ultrasound. Gut 1992; 33: 92-97.
29. Soy D, Beal SL, Sheiner LB,. Population one-compartment pharmacokinetic analysis with missing dosage data. Clin Pharmacol Ther 2004; 76: 441-451.
30. Holford NH,. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329-332.
31. Hooker AC, Staatz CE, Karlsson MO,. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 2007; 24: 2187-2197.
32. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO,. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 143-151.
33. George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CNJ, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD,. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumours after imatinib failure. Eur J Cancer 2009; 45: 1959-1968.
34. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ,. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010; 66: 357-371.
35. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand J-P, Scigalla P, Raymond E,. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35.
36. Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, Ueda E, Ohtsu A,. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs 2009; 28: 866-875.
37. Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer J, Atkins J, Pallares C, Burgess R, Tye L, Selaru P, Wang E, Chao R, Govindan R,. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009; 101: 1543-1548.
38. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG,. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338.
39. Lankheet NAG, Knapen LM, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR,. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Ther Drug Monit 2014; 36: 326-334.
40. Van Hasselt JGC, Boekhout AH, Beijnen JH, Schellens JHM, Huitema ADR,. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity. Clin Pharmacol Ther 2011; 90: 126-132.
41. Van Hasselt JGC, Gupta A, Hussein Z, Beijnen JH, Schellens JHM, Huitema ADR,. Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia. Br J Clin Pharmacol 2013; 76: 412-424.